Lifecore Biomedical (FRA:LDE) Cyclically Adjusted FCF per Share: €-0.74 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LDE Lifecore Biomedical Inc FRA:LDE
51 GF Score
Price €3.76
GF Value €5.62
! 5 Warning Signs
View Full Analysis

What is Lifecore Biomedical Cyclically Adjusted FCF per Share?

Lifecore Biomedical FRA:LDE +1.08% 51 Cyclically Adjusted FCF per Share is €-0.74 as of Mar. 2026. GuruFocus rates FRA:LDE with a GF Score™ of 51/100 and a GF Value™ of €5.62. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Lifecore Biomedical's adjusted free cash flow per share for the three months ended in Mar. 2026 was €0.083. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.74 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -23.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -50.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Lifecore Biomedical was 138.10% per year. The lowest was -75.30% per year. And the median was -12.60% per year.

As of today (2026-07-30), Lifecore Biomedical's current stock price is €3.76. Lifecore Biomedical's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.74. Lifecore Biomedical's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Lifecore Biomedical was 374.33. The lowest was 39.83. And the median was 64.52.


Lifecore Biomedical  (FRA:LDE) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Lifecore Biomedical was 374.33. The lowest was 39.83. And the median was 64.52.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Lifecore Biomedical Cyclically Adjusted FCF per Share Related Terms


Lifecore Biomedical Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Lifecore Biomedical's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical Cyclically Adjusted FCF per Share Chart

Lifecore Biomedical Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.16 -0.47 -0.63 -0.73 -0.81

Lifecore Biomedical Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.83 -0.81 -0.73 0.00 -0.74

FRA:LDE vs DERM, ADCT, ANIK: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Cyclically Adjusted Price-to-FCF falls into.


FRA:LDE
51GF Score
Lifecore Biomedical Inc FRA:LDE
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lifecore Biomedical Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lifecore Biomedical's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.083/330.2130*330.2130
=0.083

Current CPI (Mar. 2026) = 330.2130.

Lifecore Biomedical Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201605 0.026 240.229 0.036
201608 0.141 240.849 0.193
201611 -0.119 241.353 -0.163
201702 0.438 243.603 0.594
201705 -0.223 244.733 -0.301
201708 -0.069 245.519 -0.093
201711 -0.025 246.669 -0.033
201802 0.077 248.991 0.102
201805 -0.404 251.588 -0.530
201808 -0.379 252.146 -0.496
201811 -0.049 252.038 -0.064
201902 -0.058 252.776 -0.076
201905 -0.398 256.092 -0.513
201908 -0.476 256.558 -0.613
201911 -0.482 257.208 -0.619
202002 0.141 258.678 0.180
202005 -0.543 256.394 -0.699
202008 0.358 259.918 0.455
202011 -0.039 260.229 -0.049
202102 -0.334 263.014 -0.419
202105 -0.224 269.195 -0.275
202108 -0.205 273.567 -0.247
202111 -0.304 277.948 -0.361
202202 -0.695 283.716 -0.809
202205 -0.383 292.296 -0.433
202208 -0.149 296.171 -0.166
202211 -0.205 297.711 -0.227
202302 -0.580 300.840 -0.637
202305 -0.286 304.127 -0.311
202308 -0.404 307.026 -0.435
202311 -0.075 307.051 -0.081
202402 -0.197 310.326 -0.210
202405 0.149 314.069 0.157
202408 -0.119 314.796 -0.125
202411 -0.235 315.493 -0.246
202502 -0.110 319.082 -0.114
202505 0.078 321.465 0.080
202509 0.001 324.800 0.001
202512 0.000 324.054 0.000
202603 0.083 330.213 0.083

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.74 mean?
Lifecore Biomedical (FRA:LDE) has a Cyclically Adjusted FCF per Share of €-0.74 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Lifecore Biomedical and its competitors.
Is Lifecore Biomedical's Cyclically Adjusted FCF per Share too high?
Lifecore Biomedical's current Cyclically Adjusted FCF per Share is €-0.74. Overall, Lifecore Biomedical has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's Cyclically Adjusted FCF per Share compare to DERM and ADCT?
Lifecore Biomedical's Cyclically Adjusted FCF per Share of €-0.74 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Lifecore Biomedical and its competitors. Lifecore Biomedical's current Cyclically Adjusted FCF per Share is €-0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Lifecore Biomedical (FRA:LDE) has a current Cyclically Adjusted FCF per Share of €-0.74. The stock's GF Value™ is €5.62, compared to a current price of €3.76 — trading 33.1% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.74. Lifecore Biomedical's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Lifecore Biomedical (FRA:LDE), the current Cyclically Adjusted FCF per Share is €-0.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lifecore Biomedical (FRA:LDE) Overvalued in 2026?

Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued. The current stock price of €3.76 is trading 33.1% below its estimated GF Value™ of €5.62.

Key valuation signals for FRA:LDE:

  • Cyclically Adjusted FCF per Share: €-0.74
  • GF Value™: €5.62 vs. price of €3.76 (33.1% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the FRA:LDE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lifecore Biomedical Business Description

Other Exchanges LFCR:USA
Address 3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
51GF Score

Get the complete analysis for FRA:LDE

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.76
Price
€5.62
GF Value